Abstract:Background Lung cancer is the leading malignant disease and cause of cancer-related death worldwide. Most patients with lung cancer had insignificant early symptoms so that most of them were diagnosed at an advanced stage. In addition to factors such as smoking, pollution, lung microbiome and its metabolites play vital roles in the development of lung cancer. However, the interaction between lung microbiota and carcinogenesis is lack of systematically characterized and controversial. Therefore, the purpose of this study was to excavate the features of the lung microbiota and metabolites in patients and verify potential biomarkers for lung cancer diagnosis. Methods Lung tissue flushing solutions and bronchoalveolar lavage fluid samples came from patients with lung cancer and non-lung cancer. The composition and variations of the microbiota and metabolites in samples were explored using muti-omics technologies including 16S rRNA amplicon sequencing, metagenomics and metabolomics. Results The metabolomics analysis indicated that 40 different metabolites, such as 9,10-DHOME, sphingosine, and cysteinyl-valine, were statistically significant between two groups (VIP > 1 and P < 0.05). These metabolites were significantly enriched into 11 signal pathways including sphingolipid, autophagy and apoptosis signaling pathway ( P < 0.05). The analysis of lung microbiota showed that significant changes reflected the decrease of microbial diversity, changes of distribution of microbial taxa, and variability of the correlation networks of lung microbiota in lung cancer patients. In particular, we found that oral commensal microbiota and multiple probiotics might be connected with the occurrence and progression of lung cancer. Moreover, our study found 3 metabolites and 9 species with significantly differences, which might be regarded as the potential clinical diagnostic markers associated with lung cancer. Conclusions Lung microbiota and metabolites might play important roles in the pathogenesis of lung cancer, and the altered metabolites and microbiota might have the potential to be clinical diagnostic markers and therapeutic targets associated with lung cancer.

Microbiome and lung cancer: carcinogenic mechanisms, early cancer diagnosis, and promising microbial therapies

The Function and Molecular Mechanism of Commensal Microbiome in Promoting Malignant Progression of Lung Cancer

Role of Respiratory System Microbiota in Development of Lung Cancer and Clinical Application

Microbiota Regulates Pancreatic Cancer Carcinogenesis through Altered Immune Response.

Human Microbiota: a Crucial Gatekeeper in Lung Cancer Initiation, Progression, and Treatment

Microbiome Dysbiosis in Lung Cancer: from Composition to Therapy

The Human Microbiome: A Promising Target for Lung Cancer Treatment

The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy

Microbes for lung cancer detection: feasibility and limitations

Exploring the microbiome: Uncovering the link with lung cancer and implications for diagnosis and treatment

[Progress of Research on the Relationship between Lung Microbiome and Lung Cancer].

Host-Microbiome Interaction in Lung Cancer

Microbiology and Lung Cancer: A Comprehensive Review

Interplay Between the Lung Microbiome and Lung Cancer.

Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?

Microbiota in cancer: molecular mechanisms and therapeutic interventions

The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment

Emerging Clinical Relevance of Microbiome in Cancer: Promising Biomarkers and Therapeutic Targets.

Symbiotic microbial communities in various locations of the lung cancer respiratory tract along with potential host immunological processes affected

Characterizing microbiota and metabolomics analysis to identify candidate biomarkers in lung cancer

Human Microbiomes in Cancer Development and Therapy.